期刊
JOURNAL OF CLINICAL LIPIDOLOGY
卷 13, 期 3, 页码 374-392出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2019.04.010
关键词
Lipoprotein (a); Lp(a); Biomarker; Atherosclerotic cardiovascular disease; Cut points; Cardiovascular risk; Coronary heart disease; Myocardial infarction; Stroke; Calcific valvular aortic disease; Primary prevention; Secondary prevention; Treatment; Lifestyle; Scientific statement
Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in 20% of the population. Observational and genetic evidence strongly support a causal relationship between high plasma concentrations of Lp(a) and increased risk of atherosclerotic cardiovascular disease related events, such as myocardial infarction and stroke, and valvular aortic stenosis. In this scientific statement, we review an array of evidence-based considerations for testing of Lp(a) in clinical practice and the utilization of Lp(a) levels to inform treatment strategies in primary and secondary prevention. (C) 2019 National Lipid Association. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据